Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Want to cut your energy bills? Here’s how five experts are doing it 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
CAMBRIDGE, Mass., Feb. 28, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the company is scheduled to present at the Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017 at 2:00 p.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at agios.com. A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Contacts Investors: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
